Navigation Links
Laureate Pharma to Add More Manufacturing Capacity
Date:9/18/2008

- Laureate To Add Single-Use Bioreactor (S.U.B.) To Its Portfolio Of Assets

-

PRINCETON, N.J., Sept. 18 /PRNewswire/ -- Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that it is increasing its existing manufacturing capacity by adding two Single-Use Bioreactors (S.U.B.). Acquisition of a 250L and a 1000L S.U.B. will give Laureate greater flexibility in meeting the varying needs of its clients.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080131/NETH020LOGO )

The S.U.B. is a single-use alternative to conventional stirred tank bioreactors. The S.U.B. consists of a permanent stainless steel outer support container and a S.U.B. Bioprocess Container (BPC(R)), integrated with an existing bioreactor control system. This makes the S.U.B. a flexible, rapid and economic option to update or increase the bioreactor capacity. The S.U.B. will supplement Laureate's current single-use bioreactors -- Wave Bioreactors(R) and hollow-fiber systems -- as well as the conventional stainless steel stirred-tank bioreactors.

"We are excited about adding the S.U.B. to increase our bioreactor capacity. It is a scalable technology that will support the demand from our growing client base and meet their needs and manufacturing objectives," said Robert J. Broeze, Ph. D., President & Chief Executive Officer of Laureate. "The HyClone S.U.B. provides us with all the advantages of single-use bioprocessing, while maintaining aspect ratios and agitation mechanisms comparable to traditional stainless steel stirred-tank bioreactors."

About Laureate Pharma, Inc.

Laureate Pharma is a full-service biopharmaceutical development and protein production company located in Princeton, New Jersey. Laureate Pharma offers superior bioprocessing services that accelerate new products from development through production. Laureate provides a wide range of specialized services from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services, and regulatory support. Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. For more information, contact Michael Cavanaugh, Vice President Sales, Marketing, and Business Development at (609) 919-3400, or info@laureatepharma.com or visit http://www.laureatepharma.com.


'/>"/>
SOURCE Laureate Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ARUP Laboratories ARUP Consult(R) Recognized as a Computerworld Honors Program Laureate
2. Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
3. Laureate Pharma Reports Record Growth for 2007
4. Laureate Pharma Appoints Gary Swan as Vice President of Operations
5. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
6. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
7. American Scientists Named as Laureates of the 2008 (24th) Japan Prize
8. Thomson Scientific Salutes Nobel Laureate Prize Winners, Many of Whom Were Selected as Thomson Scientific Laureates in 2006
9. DFB Sells Coria Labs to Valeant Pharmaceuticals
10. Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008
11. Pharmatek Announces Official Opening of New Highly-Potent & Cytotoxic Development and Manufacturing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):